Notably, the NLRP3 inflammasome has been pharmacologically validated as a therapeutic target in RA, where its aberrant activation drives synovitis and bone erosion, while targeted inhibition significantly ameliorates disease severity in preclinical models (7, 8). The gene discussed is NLRP3; the disease is rheumatoid arthritis.